Enuzovimab - CISMeF

Preferred Label : Enuzovimab;

NCIt synonyms : Anti-SARS-CoV-2 S Protein Monoclonal Antibody HFB30132A; Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody HFB30132A;

NCIt definition : A neutralizing monoclonal antibody directed against the spike (S) protein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, enuzovimab specifically targets and binds to the SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2.;

UNII : D474BW0A5E;

CAS number : 2531098-91-4;

Molecule name : HFB 30132A; HFB-30132A;

NCI Metathesaurus CUI : CL1770605;

Details

Origin ID

C182100;

UMLS CUI

C5667303;

Currated CISMeF NLP mapping
- enuzovimab [MeSH Supplementary Concept]
- enuzovimab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- enuzovimab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
has_target
- SARS-CoV-2 Spike Glycoprotein [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients